Skip to main content
HairCited

非那雄胺(Finasteride) 用于 雄激素性脱发

A

基于129项研究(16项荟萃分析、13项RCT),共18,623名参与者。106/129项研究显示积极效果。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dfinasteride\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

结论

Finasteride has very strong evidence supporting its effectiveness for androgenetic alopecia and is considered a well-established first-line option backed by decades of research.

  • 106 out of 129 studies show positive effects — one of the most studied hair loss interventions
  • 16 meta-analyses and 13 RCTs provide a robust evidence base across 18,623 participants
  • Works by reducing DHT, the hormone primarily responsible for pattern hair loss
  • Topical finasteride formulations are being researched as an alternative to oral use

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None 效果: None None

研究人群: women with androgenetic alopecia (female pattern hair loss)

non-randomized controlled trial n=60 16 weeks Open-label
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of …
Dose: Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); vs: Placebo 效果: All groups showed significant decrease in HLSS and increase in hair density post-treatment (p<0.001) p<0.001
randomized controlled trial n=45 16 weeks Open-label
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in …
Dose: Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi vs: Placebo 效果: Groups A and C showed significant improvement on Sinclair scale and trichoscopic hair density; Group None
Review
Male and female pattern hair loss.
Dose: None vs: Placebo 效果: None None
randomized controlled trial n=45 Open-label
Clinical efficacy of microneedle combined with 5% Minoxidil solution and finasteride in the treatment of …
Dose: Group A: 5% Minoxidil alone; Group B: 5% Minoxidil + Finasteride; Group C: Microneedling + 5% Minoxi vs: Placebo 效果: Hair density and hair shaft diameter increased in all groups; Group C superior to Group A in Norwood p<0.01

Key Statistics

206

研究数量

24777

受试者

Positive

A

等级

Referenced Papers

Aesthetic plastic surgery 2025 14 次引用
Anais brasileiros de … 2025 7 次引用
International journal of … 2025 5 次引用
Journal of cosmetic … 2025 3 次引用
European journal of … 2025 3 次引用
Australian prescriber 2025 2 次引用
Skin appendage disorders 2025 1 次引用
Nature reviews. Disease … 2025
Annals of dermatology 2025
International journal of … 2024 39 次引用
Indian journal of … 2024 14 次引用
Dermatology (Basel, Switzerland) 2024 14 次引用
Journal of cosmetic … 2024 11 次引用
Journal of clinical … 2024 10 次引用
Facial plastic surgery … 2024 8 次引用
American family physician 2024 8 次引用
Photodermatology, photoimmunology & … 2024 8 次引用
International journal of … 2024 5 次引用
Drugs 2023 221 次引用
JAAD international 2023 80 次引用
Clinical, cosmetic and … 2023 58 次引用
American journal of … 2023 41 次引用
Anais brasileiros de … 2023 29 次引用
Dermatology and therapy 2023 23 次引用
International journal of … 2023 5 次引用
Journal der Deutschen … 2023 5 次引用
Journal of cosmetic … 2023 3 次引用
BMJ case reports 2023 2 次引用
Clinics in plastic … 2023 1 次引用
International journal of … 2023 1 次引用
The Journal of … 2022 65 次引用
Faculty reviews 2022 44 次引用
Dermatologic therapy 2022 41 次引用
Archivos espanoles de … 2022 9 次引用
Cureus 2022 3 次引用
Facial plastic surgery … 2022
Journal of cutaneous … 2021 44 次引用
Journal of the … 2021 42 次引用
Expert opinion on … 2020 147 次引用
Fertility and sterility 2020 94 次引用
Neurobiology of stress 2020 72 次引用
Facial plastic surgery … 2020 15 次引用
Dermatologic clinics 2020 15 次引用
Alternative therapies in … 2020 11 次引用
Journal of cosmetic … 2019 100 次引用
Assay and drug … 2019 19 次引用
The aging male … 2019 19 次引用
International journal of … 2018 129 次引用
Indian journal of … 2018 79 次引用
Lasers in medical … 2018 75 次引用
Expert opinion on … 2018 38 次引用
Endocrine 2017 442 次引用
JAMA dermatology 2017 121 次引用
Current clinical pharmacology 2017 62 次引用
Actas dermo-sifiliograficas 2017 17 次引用
Deutsches Arzteblatt international 2016 99 次引用
The Cochrane database … 2016 18 次引用
Indian journal of … 2016 8 次引用
The Medical clinics … 2015 66 次引用
Current problems in … 2015 8 次引用
Der Internist 2015
Lasers in surgery … 2014 243 次引用
Journal of cutaneous … 2014 168 次引用
Expert opinion on … 2014 57 次引用
Current opinion in … 2014 43 次引用
Journal of drugs … 2014 26 次引用
Giornale italiano di … 2014 8 次引用
Indian journal of … 2013 196 次引用
Dermatologic clinics 2013 78 次引用
Journal of cosmetic … 2013 62 次引用
Facial plastic surgery … 2013 16 次引用
International journal of … 2013
Expert opinion on … 2010 264 次引用
Current opinion in … 2009 54 次引用
Seminars in cutaneous … 2009 4 次引用
American family physician 2009
Nihon rinsho. Japanese … 2008 6 次引用
Endocrinology and metabolism … 2007 33 次引用
Acta dermatovenerologica Alpina, … 2005
Revue medicale de … 2004
Praxis 2003 28 次引用
American family physician 2003
Molecular and cellular … 2002
American journal of … 2000 18 次引用
Southern medical journal 2000
International journal of … 1999
American family physician 1999
Journal of the … 1999
Current pharmaceutical design 1999
Journal of cutaneous … 1999
Dermatologic clinics 1998 121 次引用
Annales de dermatologie … 1997

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

常用剂量

hairloss:
1 mg/day oral

上限: 5 mg/day (BPH dose)

研究中使用的剂量

剂量 持续时间 效果 N
None -- Neutral --
None -- Neutral --
Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); 16 weeks Positive 60
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
None -- Positive --
Group A: 5% Minoxidil alone; Group B: 5% Minoxidil + Finasteride; Group C: Microneedling + 5% Minoxi -- Positive 45
None -- Positive --
various across included studies (2015-2024) -- Positive --

最佳服用时间: Once daily at the same time, with or without food

Safety & Side Effects

已报告的副作用

  • Decreased libido (2-4% of users)
  • Erectile dysfunction (1-3% of users)
  • Decreased ejaculate volume
  • Breast tenderness or gynecomastia (rare)
  • Depression or mood changes (rare, debated)

已知相互作用

  • No significant drug-drug interactions identified
  • May affect PSA test results (reduces PSA by ~50%)
  • Contraindicated in pregnancy (Category X teratogen)

可耐受最高摄入量: 5 mg/day (BPH dose)

在开始服用任何补充剂之前,请务必咨询您的医疗保健提供者。

Frequently Asked Questions

Does 非那雄胺(Finasteride) help with 雄激素性脱发?
Based on 206 studies with 24,777 participants, there is strong evidence from multiple clinical trials that 非那雄胺(Finasteride) may support 雄激素性脱发 management. Our evidence grade is A (Strong Evidence).
How much 非那雄胺(Finasteride) should I take for 雄激素性脱发?
Studies have used various dosages. A commonly studied range is 1 mg/day oral. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 非那雄胺(Finasteride)?
Reported side effects may include Decreased libido (2-4% of users), Erectile dysfunction (1-3% of users), Decreased ejaculate volume, Breast tenderness or gynecomastia (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 非那雄胺(Finasteride) and 雄激素性脱发?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 206 peer-reviewed studies with 24,777 total participants. The overall direction of effect is positive.

Related Evidence

FDA 免责声明: 这些声明未经美国食品药品监督管理局(FDA)评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析,不构成医疗建议。在开始任何补充剂方案之前,请务必咨询您的医疗保健提供者。